Akhlaghi Mohammadreza, Dehghani Alireza, Kianersi Farzan, Khalili Mohammad Reza, Tohidi Mohammad, Jahanbani-Ardakani Hamidreza
Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Ophthalmology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
J Curr Ophthalmol. 2024 Oct 16;36(1):61-65. doi: 10.4103/joco.joco_13_22. eCollection 2024 Jan-Mar.
To evaluate the efficacy of eplerenone in central serous chorioretinopathy (CSCR) patients in a clinical trial design.
In this double-blind clinical trial, naive acute. CSCR patients were divided into two groups: treatment with eplerenone 25 mg daily in the 1 week followed by 50 mg for the next 3 weeks and placebo group. Best-corrected visual acuity (BCVA), central macular thickness (CMT), macular volume (MV), and choroidal thickness (CT) were measured before and after 1 month of the intervention using the optical coherence tomography technique.
Thirty-one CSCR (male: 23, female: 8) and 25 CSCR patients (male: 18, female: 7) with the mean age of 35.65 ± 5.94 and 37.08 ± 6.41 years were recruited and divided randomly into treatment and placebo groups, respectively. BCVA improved significantly in the treatment group (from 0.28 ± 0.26 to 0.11 ± 0.14, = 0.002) compared with the placebo group (from 0.31 ± 0.26 to 0.21 ± 0.14, = 0.052). Although CT, CMT, and MV improved significantly in each group, there were no significant differences between the groups.
In this study, we found favorable short-term clinical effects of eplerenone in acute CSCR patients, showing the pivotal role of mineralocorticoid receptors in the retina.
在一项临床试验设计中评估依普利酮治疗中心性浆液性脉络膜视网膜病变（CSCR）患者的疗效。
在这项双盲临床试验中，初发急性CSCR患者被分为两组：一组在第1周每日服用25 mg依普利酮，接下来3周每日服用50 mg；另一组为安慰剂组。使用光学相干断层扫描技术在干预1个月前后测量最佳矫正视力（BCVA）、中心黄斑厚度（CMT）、黄斑体积（MV）和脉络膜厚度（CT）。
招募了31例CSCR患者（男性23例，女性8例）和25例CSCR患者（男性18例，女性7例），平均年龄分别为35.65±5.94岁和37.08±6.41岁，分别随机分为治疗组和安慰剂组。与安慰剂组（从0.31±0.26提高到0.21±0.14，P = 0.052）相比，治疗组的BCVA显著改善（从0.28±0.26提高到0.11±0.14，P = 0.002）。尽管每组的CT、CMT和MV均有显著改善，但两组之间无显著差异。
在本研究中，我们发现依普利酮对急性CSCR患者有良好的短期临床效果，表明盐皮质激素受体在视网膜中起关键作用。
